GA GENOTYPE OF THE ARG280HIS POLYMORPHISM ON
THE XRCC1 GENE: GENETIC SUSCEPTIBILITY GENOTYPE
IN DIFFERENTIATED THYROID CARCINOMAS?
Kirnap NG1,*, Tutuncu NB1,2, Yalcin Y2, Cebi HPB2, Tutuncu T2,3, Nar A1, Verdi H2, Atac FB2
*Corresponding Author: Nazlı G. Kirnap, M.D., Department of Endocrinology and Metabolism,
Başkent University Faculty of Medicine, Taskent Caddesi No. 77, Bahcelievler, 06490, Ankara, Turkey.
Tel.: +90-(0)312-203-6868. Fax: +90-(0)312-304-2700. E-mail: kirnapnazli@hotmail.com
page: 73
|
|
REFERENCES
1. Davies L, Welch HG. Increasing incidence of thyroid
cancer in the United States 1973-2002. JAMA. 2006;
295(18): 2164-2167.
2. Akulevich NM, Saenko VA, Rogounovitch TI, Drozd
VM, Lushnikov EF, Ivanov VK, et al. Polymorphisms
of DNA damage response genes in radiation-related
and sporadic papillary thyroid carcinoma. Endocr
Relat Cancer. 2009; 16(2): 491-503.
3. Lence-Anta JJ, Xhaard C, Ortiz RM, Kassim H,
Pereda CM, Turcios S, et al. Environmental, lifestyle,
and anthropometric riskfactors for differentiated thyroid
cancer in cuba: a case-control study. Eur Thyroid
J. 2014; 3(3): 189-196.
4. Bashir K, Sarwar R, Fatima S, Saeed S, Mahjabeen
I, Akhtar Kayani M. Haplotype analysis of XRCC1
gene polymorphisms and the risk of thyroid carcinoma.
J BUON. 2018; 23(1): 234-243.
5. Matsuse M, Mitsutake N, Tanimura S, Ogi T, Nishihara
E, Hirokawa M, et al. Functional characterization of
the novel BRAF complexmutation, BRAF (V600
delinsYM), identified in papillarythyroid carcinoma.
Int J Cancer. 2013; 132(3): 738-743.
6. Hu Z, Hu X, Long J, Su L, Wei B. XRCC1 polymorphisms
and differentiated thyroid carcinoma risk:
A meta-analysis. Gene. 2013; 528(2): 67-73. 7. Du Y, Han LY, Li DD, Liu H, Gao YH, Sun D.
Associations between XRCC1 Arg399Gln, Arg194Trp,
and Arg280His polymorphisms and risk of differentiated
thyroid carcinoma: A meta-analysis. Asian Pac J
Cancer Prev. 2013; 14(9): 5483-5487.
8. Chang-Claud J, Popanda O, Tan XL, Kropp S,
Helmbold I, von Fournier D, et al. Association
between polymorphisms in the DNA repair genes,
XRCC1, APE1, and XPD and acute side effects of
radiotherapy in breast cancer patients. Clin Cancer
Res. 2005; 11(13): 4802-4809.
9. Zhai W, Feng R, Wang H, Wang Y. Note of clarification
of data in the papertitled X-ray repair cross-complementing
group 1 codon 399 polymorphism and
lung cancer risk: An updated meta-analysis. Tumour
Biol. 2015; 36(5): 3179-3189.
10. Bu T, Liu L, Sun Y, Zhao L, Peng Y, Zhou S, et al.
XRCC1 Arg399Gln polymorphism confers risk of
breast cancer in American population: A meta-analysis
of 10846 cases and 11723 controls. PLoS One.
2014; 9(1): e86086.
11. Tian Z, Li YL, Liu JG. XRCC1 Arg399Gln polymorphism
contributes to increased risk of colorectal
cancer in Chinese population. Mol Biol Rep. 2013;
40(7): 4147-4151.
12. Ho T, Li G, Lu J, Zhao C, Wei Q, Sturgis EM.
Association of XRCC1 polymorphisms and risk
of differentiated thyroid carcinoma: A case-control
analysis. Thyroid. 2009; 19(2): 129-135.
13. Chiang FY, Wu CW, Hsiao PJ, Kuo WR, Lee KW,
Lin LC, et al. Association between polymorphisms
in DNA base excision repair genes XRCC1, APE1,
and ADPRT and differentiated thyroid carcinoma.
Clin Cancer Res. 2008; 14(18): 5919-5924.
14. Garcia-Quispes WA, Perez-Machado G, Akdi A,
Pastor S, Galofre P, Biarnes F, et al. Association
studies of OGG1, XRCC1, XRCC2 and XRCC3
polymorphisms with differentiated thyroid cancer.
Mutat Res. 2011: 709-710: 67-72.
15. Zhu QX, Bian JC, Shen Q, Pastor S, Galofré P, Zhang
HW, et al. Genetic polymorphisms in X-ray repair
cross-complementing gene 1 and susceptibility to
papillary thyroid carcinoma. Zhonghua Liu Xing
Bing Xue Za Zhi. 2004; 25(8): 702-705.
16. Ryu RA, Tae K, Min HJ, Jeong JH, Cho SH, Lee SH,
et al. XRCC1 polymorphisms and risk of papillary
thyroid carcinoma in a Korean sample. J Korean Med
Sci. 2011; 26(8): 991-995.
17. Zhu J, Qi P, Li Z. Interaction between XRCC1 gene
polymorphisms and obesity on susceptibility to papillary
thyroid cancer in Chinese Han population. Cell
Physiol Biochem. 2018; 49(2): 638-644.
18. Sigurdson AJ, Land CE, Bhatti P, Pineda M, Brenner
A, Carr Z, et al. Thyroid nodules, polymorphic variants
in DNA repair and RET-related genes, and interaction
with ionizing radiation exposure from nuclear
tests in Kazakhstan. Radiat Res. 2009; 171(1): 77-88.
19. Wang X, Zhang K, Liu X, Liu B, Wang Z. Association
between XRCC1 and XRCC3 gene polymorphisms
and risk of thyroid cancer. Int J Clin Exp Pathol. 2015;
8(3): 3160-3167.
20. Wang C, Ai Z. Association of XRCC1 polymorphisms
with thyroid cancer risk. Tumour Biol. 2014;35:4791-7.
21. Yan L, Li Q, Li X, Ji H, Zhang L. Association studies
between XRCC1, XRCC2, XRCC3 polymorphisms
and differentiated thyroid carcinoma. Cell Physiol
Biochem. 2016; 38(3): 1075-1084.
22. Fan J, Otterlei M, Wong HK, Tomkinson AE, Wilson
DM 3rd. XRCC1 co-localizes and physically interacts
with PCNA. Nucleic Acid Res. 2004; 32(7): 2193-
2201.
23. Caldecott KW. XRCC1 and DNA strand repair. DNA
Repair (Amst). 2003; 2(9): 955-969.
24. Hung RJ, Hall J, Brennan P, Boffetta P. Genetic polymorphism
in the base excision repair pathway and
cancer risk. A HuGE review. Am J Epidemiol. 2005;
162(10): 925-942.
25. Yan L, Yanan D, Donglan S, Na W, Rongmiao Z,
Zhifeng C. Polymorphisms of XRCC1 gene and risk
of gastric cardiac adenocarcinoma. Dis Esophagus.
2009; 22(5): 396-401.
26. Takanami T, Nakamura J, Kubota Y, Horiuchi S. The
Arg280His polymorphism in X-ray repair cross-complementing
gene 1 impairs DNA repairability. Mutat
Res. 2005; 582(1-2): 135-145.
27. Zhang K, Zhou B, Wang Y, Rao L, Zhang L. The
XRCC1 Arg280His polymorphism contributes to
cancer susceptibility: An update by meta-analysis of
53 individual studies. Gene. 2012; 510(2): 93-101.
28. Qian K, Liu KJ, Xu F, Chen XY, Chen GN, Yi WJ,
et al. X-ray repair cross-complementing group 1
(XRCC1) genetic polymorphisms and thyroid carcinoma
risk: A meta-analysis. Asian Pac J Cancer Prev.
2012; 13(12): 6385-6390.
29. Yang D, Han L-Y, Li D-D, Liu H, Gao YH, Sun
DJ. Associations between XRCC1 Arg399Gln,
Arg194Trp, and Arg280His polymorphisms and risk
of differentiated thyroid carcinoma: A meta-analysis.
Asian Pac J Cancer Prev. 2013; 14(9): 5483-5487. 30. Hu Z, Hu X, Long J, Su L, Wei B. XRCC1 poly-morphisms
and differentiated thyroid carcinoma risk: A
meta-analysis. Gene. 2013; 528(2): 67-73.
31. Bao Y, Jiang L, Zhou JY, Zou JJ, Zheng JY, Chen XF,
et al. XRCC1 gene polymorphisms and the risk of differentiated
thyroid carcinoma (DTC): A meta-analysis
of case-control studies. PLos One. 2013; 8(5): e64851.
32. Wang C, Ai Z. Association of XRCC1 polymorphisms
with thyroid cancer risk. Tumor Biol. 2014; 35(5):
4791-4797.
33. Zhou W, Liu G, Miller DP, Thurston SW, Xu LL,
Wain JC, et al. Polymorphisms in the DNA repair
genes XRCC1 and ERCC2, smoking and lung cancer
risk. Cancer Epidemiol Biomarkers Prev. 2003; 12(4):
359-365.
34. Dailey ME, Lindsay S, Skahen R. Relation of thyroid
neoplasms to Hashimoto disease of the thyroid gland.
Arch Surg. 1955; 70(2): 291-297.
35. Cheema Y, Olson S, Elson D, Chen H. What is the
biology and optimal treatment for papillary microcarcinoma
of the thyroid? J Surg Res. 2006; 134(2):
160-162.
36. Jankovic B, Le KT, Hershman JM. Clinical Review:
Hashimoto’s thyroiditis and papillary thyroid carcinoma:
Is there a correlation? J Clin Endocrinol Metab.
2013; 98(2): 474-482.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
